Absent very positive interium results it soulnds like it will take thru 2017 for Reduce-it to be completed and probably another year for anlaysis and waiting on our good friends at FDA. Even with costs trending down each quarter, absent dramatically better perscrition numbers and/or a partner I don't see how we make it through study completion. Could some of you with more details on costs and revenues paste this on a time line for folks to see?
The repeated FDA actions and inactions have systematically undermined and discredited the company in the eyes of investors, doctors and patients. The damage is real and not easily reversed absent some truely extraordinary results and a virtually unpresedented change in momentum. Amarin is the victum of some truely profound incompetence or evil intentions at FDA and/or has found itself to be the unfortunate pivot point in FDA policy change regarding evidenced based medicine.
News 
Market Data 
Discover 
AI
